Short Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Grows By 17.6%

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 450,000 shares, a growth of 17.6% from the August 31st total of 382,600 shares. Based on an average trading volume of 116,500 shares, the days-to-cover ratio is presently 3.9 days.

Milestone Pharmaceuticals Stock Up 0.7 %

MIST traded up $0.01 during trading on Monday, reaching $1.54. The company had a trading volume of 6,404 shares, compared to its average volume of 209,502. The company has a debt-to-equity ratio of 1.61, a current ratio of 19.13 and a quick ratio of 19.13. Milestone Pharmaceuticals has a 12 month low of $1.12 and a 12 month high of $3.52. The business’s fifty day moving average price is $1.45 and its 200 day moving average price is $1.54. The company has a market cap of $82.02 million, a P/E ratio of -1.22 and a beta of 1.71.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. Equities analysts anticipate that Milestone Pharmaceuticals will post -0.71 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on MIST shares. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Milestone Pharmaceuticals in a research note on Thursday, August 22nd. Rodman & Renshaw started coverage on shares of Milestone Pharmaceuticals in a research note on Thursday, August 22nd. They set a “buy” rating and a $9.00 price objective on the stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Milestone Pharmaceuticals stock. Lion Point Capital LP grew its holdings in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 1.7% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,340,207 shares of the company’s stock after purchasing an additional 40,000 shares during the period. Milestone Pharmaceuticals comprises approximately 5.6% of Lion Point Capital LP’s investment portfolio, making the stock its 3rd biggest holding. Lion Point Capital LP owned approximately 4.39% of Milestone Pharmaceuticals worth $3,089,000 at the end of the most recent quarter. 86.18% of the stock is owned by institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.